Block Listing 6-month review
April 05 2007 - 5:50AM
UK Regulatory
RNS Number:4874U
Hikma Pharmaceuticals Plc
05 April 2007
Block Listing - Six Monthly Review
Name of Company: Hikma Pharmaceuticals PLC
Name of scheme: Hikma Pharmaceuticals PLC 2004 Stock Option Plan
Period of return: From: 10 October 2006 To: 5 April 2007
Balance under block scheme: 3,193,200 ordinary shares of 10 pence each
The amount by which the block scheme has been increased, Nil
if the scheme has been increased since the date of the
last return:
Number of securities issued/allotted under scheme during 1,473,800 ordinary shares of 10 pence each
period:
Balance under scheme not yet issued/allotted at end of 1,719,400 ordinary shares of 10 pence each
period
Number and class of securities originally listed and the 166,537,951 ordinary shares of 10 pence each originally
date of admission listed on 1 November 2005
Total number of securities in issue at the end of the 169,137,407 ordinary shares of 10 pence each
period
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Henry Knowles, Company Secretary +44 20 7399 2760
Susan Ringdal, Investor Relations Director
Notes to Editors
About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ("MENA") region and Europe. In 2006, the Group
had revenue of $317 million and profit attributable to shareholders of $54.5
million. For news and other information, please visit www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRUUUBCCUPMUBA
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024